View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
September 21, 2022

Top tweets: Tea consumption and mortality risk – and more

Clinical Trials Arena lists five of the top tweets on cardiology in August 2022 based on data from GlobalData’s Pharmaceuticals Influencer Platform.

The top tweets are based on total engagements (likes and retweets) received on tweets from more than 240 cardiology experts tracked by GlobalData’s Pharmaceuticals Influencer platform during August 2022.

1. Eric Topol’s tweet on the association of tea consumption with mortality risk

Eric Topol, a physician and scientist, shared a study that assessed the relationship between tea consumption and all-cause and cause-specific mortality. The study also assessed the potential effect modification by genetic variation in caffeine digestion.

The participants of the study included 498,043 males and females between the ages of 40 and 69 who responded to a baseline touchscreen survey conducted between 2006 to 2010. Self-reported tea consumption and mortality from all causes including cancer, cardiovascular disease, ischemic heart disease, stroke, and respiratory disease, were used as the basis for the analysis.

The study was funded by the National Cancer Institute Intramural Research Program. It concluded that increased tea consumption was related to lower mortality risk among people who drank two or more cups of tea per day during a median follow-up of 11.2 years. The findings suggested that tea can be a healthy food choice, even at increased intake levels.

Username: Eric Topol

Twitter handle: @EricTopol

Likes: 1,967

Retweets: 508

2. Pradeep Natarajan’s tweet on the developments related to imaging and targeted therapies for recurrent pericarditis

Pradeep Natarajan, a cardiologist, shared an article on the advancements made in targeted therapies and imaging that have helped in the management of recurrent pericarditis, a condition that leads to the inflammation of the tissue sac surrounding the heart. A review was performed using the PubMed and Cochrane databases for all studies, management recommendations, meta-analyses, and review papers on recurrent pericarditis published up to April 2022.

The review indicated that the effectiveness of interleukin-1 blockers in treating recurrent pericarditis has been demonstrated in recent clinical studies and registry data following the 2015 European Society of Cardiology guidelines for the identification and therapy of pericardial illnesses.

Furthermore, the effectiveness of cardiac magnetic resonance imaging in the diagnosis, risk classification, and management of patients suffering from recurrent pericarditis has also been supported by fresh observational data. The review indicated the importance of cardiac magnetic resonance imaging and interleukin-1 blockers that have brought a paradigm shift in the treatment of recurrent pericarditis.

Username: Pradeep Natarajan

Twitter handle: @pnatarajanmd

Likes: 199

Retweets: 79

3. Julia Grapsa’s tweet on aortic valve replacement in a patient with a criss-crossed heart

Julia Grapsa, a cardiologist, shared an article on a case report on aortic valve replacement performed through a catheter in a 77-year-old woman patient with a criss-crossed heart (CCH), a rare congenital heart disease. The patient was evaluated for transcatheter aortic valve replacement (TAVR) caused by symptomatic severe aortic regurgitation (AR). She exhibited symptoms of dizziness and exertional dyspnea, which were consistent with the functional class III classification of the New York Heart Association (NYHA).

The management and treatment approach for the patient required extensive evaluation conducted through different imaging techniques and coordination with an interdisciplinary team. The report highlighted the significance of TAVR as an alternative to surgical valve replacement in patients with anatomical anomalies or congenital heart disorders such as CCH.

Further, the report suggested that TAVR was effective in treating symptomatic native aortic valve regurgitation (NAVR) in an inoperable patient with complex anatomy, despite complicating characteristics such as the aneurysmatic aorta, aberrant aortic annulus and left atrioventricular connection.

Username: Julia Grapsa

Twitter handle: @JGrapsa

Likes: 121

Retweets: 39

4. Philippe Pibarot’s tweet on the use of mitral valve transcatheter in treating atrial functional mitral regurgitation

Philippe Pibarot, a professor at the Department of Medicine of Laval University, shared a research paper that analysed the use of mitral valve transcatheter edge-to-edge repair (M-TEER) in treating patients with atrial functional mitral regurgitation (aFMR).

The paper analysed baseline characteristics and two-year results in aFMR from 1,608 FMR patients and compared it with non-aFMR and ventricular FMR patients. It also analysed the impact of right ventricular dysfunction (RVD) on the results of M-TEER.

Out of the 1,608 patients, 126 or 7.8% who received M-TEER treatment were classified as having aFMR. The procedural success in these patients was 87.2%, while the two-year survival rate was 70.4% and was not significantly different in patients having non-aFMR and ventricular FMR. The paper found that aFMR can be treated effectively with M-TEER. Furthermore, RVD was found to be a potent independent predictor of two-year survival in addition to NYHA class IV.

Username: Philippe Pibarot

Twitter handle: @PPibarot

Likes: 81

Retweets: 26

5. Dr. Purvi Parwani’s tweet on the timing of heart surgery during pregnancy

Dr. Purvi Parwani, a cardiologist, shared an article that examined the relationship between the timing of heart surgery during pregnancy through an analysis of 179 studies with 386 patients, which were chosen from studies published up to February 2021.

The studies included maternal and/or foetal death cases that occurred after cardiac surgery that was performed during pregnancy. Maternal and foetal mortality was analysed for each trimester for the entire population and the patients were segmented into those who had a caesarean section (CS) before cardiac surgery (CaeSe) and those who did not undergo cardiac surgery (CarSu).

The maternal mortality after cardiac surgery was found to be 7.3%, and there were no significant differences between the subgroups CaeSe and CarSu or across the various pregnancy trimesters. Cardiac surgery performed during pregnancy was associated with high foetal mortality although it was lower in patients who had CS before surgery. Further, surgery performed during the third trimester resulted in the lowest overall foetal mortality of 10.3% compared to the overall mortality rate of 26.5%,  the article highlighted.

Username: Dr. Purvi Parwani

Twitter handle: @purviparwani

Likes: 52

Retweets: 19

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena